开拓药业-B(09939)拟折让约15.03%发行3048.75万股认购股份 净筹约4978万港元

Group 1 - The company plans to issue 30.4875 million subscription shares to Huayuan Management Consulting (Hong Kong) Limited at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% compared to the last trading price of HKD 1.93 per share [1] - The net proceeds from the subscription are approximately HKD 49.78 million, which will be used for general working capital and the Phase III clinical trial of KX-826 [1]